SCHEMBL1109641

SCHEMBL1109641

O=C(O)[C@@H](CS)NCc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
CPA3 P15088 1/20 0.50
FOLH1 Q04609 1/20 0.50
MME P08473 4/20 0.49
GAA P10253 1/20 0.46
MAPT P10636 1/20 0.46
POLB P06746 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1031027 1.00 CPA3 (0.50) CPA3FOLH1MMEGAAMAPT
SCHEMBL515921 1.00 CPA3 (0.50) CPA3FOLH1MMEGAAMAPT
Hydrochloric Acid SCHEMBL28182328 0.98 CPA3 (0.49) CPA3FOLH1MMEGAAMAPT
Hydrochloric Acid SCHEMBL1927540 0.98 CPA3 (0.49) CPA3FOLH1MMEGAAMAPT
Hydrochloric Acid SCHEMBL1927541 0.98 CPA3 (0.49) CPA3FOLH1MMEGAAMAPT
Benzenemethanethiol SCHEMBL11584239 0.95 IDO1 (0.47) CPA3FOLH1MMEGAAMAPT
SCHEMBL5505220 0.91 MME (0.49) MMEGAA
Cysteine SCHEMBL1927883 0.91 PTGS1 (0.49) CPA3FOLH1MME
SCHEMBL14777396 0.86 MEN1 (0.46) CPA3FOLH1MME
SCHEMBL14935818 0.86 FOLH1 (0.46) CPA3FOLH1MMEGAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 670 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250339569-A1 CARBONIC ANHYDRASE IX LIGANDS 3B PHARMACEUTICALS GMBH (DE) 2025-11-06 US claimed
US-12441765-B2 Peptides and medical uses thereof ANBITION S.R.L. (IT) 2025-10-14 US claimed
EP-4448544-A2 CARBONIC ANHYDRASE IX LIGANDS 3B Pharmaceuticals GmbH (DE) 2024-10-23 EP claimed
CN-116120936-B Etching liquid medicine and preparation method and application thereof 上海天承化学有限公司 2024-06-25 CN claimed
WO-2024088181-A1 LIGHT-EMITTING DEVICE AND PREPARATION METHOD THEREFOR, AND DISPLAY DEVICE TCL科技集团股份有限公司 2024-05-02 WO claimed
CN-116655730-A Derivatives of N-caproic acid-L-tyrosine-L-isoleucine- (6) -aminocaproamide for the treatment of various diseases 雅斯娜 2023-08-29 CN claimed
WO-2023111350-A2 CARBONIC ANHYDRASE IX LIGANDS 3B PHARMACEUTICALS GMBH (DE) 2023-06-22 WO claimed
CN-116120936-A Etching liquid medicine and preparation method and application thereof 上海天承化学有限公司 2023-05-16 CN claimed
WO-2022162030-A1 PEPTIDES FOR INHIBITING ANGIOGENESIS CONSIGLIO NAZIONALE DELLE RICERCHE (IT) 2022-08-04 WO claimed
CN-113880910-A Preparation method of synthetic glutathione 浙江恒腾福生物科技集团有限公司 2022-01-04 CN claimed
EP-0282219-A1 Aminoethylphosphinic acid derivatives MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) 1988-09-14 EP claimed
US-4757066-A Reduces renal toxicity SANKYO COMPANY LIMITED (JP) 1988-07-12 US claimed
EP-0272671-A2 Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors SANDOZ LTD. (CH) 1988-06-29 EP claimed
EP-0235064-A2 Aromatic compounds with amide structure, derivatives of amino-benzoic acids, hydroxybenzoic acids, cinnamic acids, urocanic acids and benzimidazoles, absorbing UVB and/or UVA Robert, Dominique (FR) 1987-09-02 EP claimed
WO-1987004923-A2 AROMATIC AMIDES ABSORBING THE U.V. ROBERT DOMINIQUE 1987-08-27 WO claimed
EP-0226304-A1 Composition containing a penem or carbapenem antibiotic SANKYO COMPANY LIMITED (JP) 1987-06-24 EP claimed
EP-0076557-B1 PEPTIDES AND PSEUDOPEPTIDES IN WHICH THE N TERMINUS BEARS TWO SUBSTITUENTS IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1985-11-13 EP claimed
US-4483807-A Process for producing a slow release composite JAPAN ATOMIC ENERGY RESEARCH INSTITUTE (JP) 1984-11-20 US claimed
US-4421744-A OPIATE RECEPTOR ANTAGONISTS IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1983-12-20 US claimed
US-3936469-A Process for preparing N-carboxylic anhydrides of amino acids KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JA) 1976-02-03 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12441765-B2 Peptides and medical uses thereof FLT1, FLT4, TEK CPA3 200/4885FOLH1 267/4885MME 182/4885
US-20250339569-A1 CARBONIC ANHYDRASE IX LIGANDS CA9, CA13, CA4 CPA3 43/4885FOLH1 36/4885MME 316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.